Frontiers in public health · 2025
Long-term symptom burden in a young, ambulatory cohort after the omicron outbreak in China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ren Simeng, Tan Yumeng, Xu Hongkun, Wang Mian, Xiang Rumei, Jin Jiayue, Han Baojin, Shi Jiaheng, Zhang Jingyu, Yang Jinliang, Tian Xin, Li Ying, Chen Jiaojiao, Zhang Wenzheng, Yang Jingqi, Wang Xin Shelley, Shi Qiuling, Liu Jie
Аннотация
INTRODUCTION: At the end of 2022, an outbreak of the Omicron BF.7 and BA.5.2 subvariants of SARS-CoV-2 occurred in China. In this prospective cohort study, we investigated the pattern of development of major symptom burden and influencing factors in infected Chinese patients.
METHODS: First-time infected outpatients were enrolled from December 7, 2022, to January 11, 2023 (N = 355). The prevalence of symptoms was monitored by a repeated patient-reported quantitative symptom survey over nine months.
RESULTS: At the onset of the infection, the most prevalent symptoms (score ≥1 on a 0-10 numeric rating scale) were fatigue (91.8%), cough (91.8%), and sore throat (91.5%) among 33 symptoms monitored. Patients with higher scores for symptom Cluster II (lack of appetite, disturbed sleep, shivering, drowsiness, sweating, nausea, depression, and anxiety) and symptom cluster V (fatigue, sore throat, dry mouth, and dizziness) reported poorer quality of life than other patients during the first month after enrolment. The most severe symptoms (score≥7) lasted during 3-9 months were depression (5.2%), fatigue (4.8%), anxiety (4.8%), runny nose (4.3%), muscle or joint pain (3.3%), nasal congestion (3.0%), disturbed sleep(2.6%). Younger age, female sex, and body mass index of at least 24 kg/m2 predicted more severe baseline symptoms and slower resolution (all p < 0.01).
CONCLUSION: This cohort study identified patterns and characteristics of symptom evolution in outpatients at 9 months post-COVID-19 diagnosis and provides targets for long-term care.
METHODS: First-time infected outpatients were enrolled from December 7, 2022, to January 11, 2023 (N = 355). The prevalence of symptoms was monitored by a repeated patient-reported quantitative symptom survey over nine months.
RESULTS: At the onset of the infection, the most prevalent symptoms (score ≥1 on a 0-10 numeric rating scale) were fatigue (91.8%), cough (91.8%), and sore throat (91.5%) among 33 symptoms monitored. Patients with higher scores for symptom Cluster II (lack of appetite, disturbed sleep, shivering, drowsiness, sweating, nausea, depression, and anxiety) and symptom cluster V (fatigue, sore throat, dry mouth, and dizziness) reported poorer quality of life than other patients during the first month after enrolment. The most severe symptoms (score≥7) lasted during 3-9 months were depression (5.2%), fatigue (4.8%), anxiety (4.8%), runny nose (4.3%), muscle or joint pain (3.3%), nasal congestion (3.0%), disturbed sleep(2.6%). Younger age, female sex, and body mass index of at least 24 kg/m2 predicted more severe baseline symptoms and slower resolution (all p < 0.01).
CONCLUSION: This cohort study identified patterns and characteristics of symptom evolution in outpatients at 9 months post-COVID-19 diagnosis and provides targets for long-term care.